NIMH St. John's wort trial, using Lichtwer Pharma product, to begin in October.
This article was originally published in The Tan Sheet
Executive Summary
NIMH ST. JOHN's WORT TRIAL TO USE LICHTWER BOTANICAL in the medication administered to participants randomized to receive active tablets. Patient enrollment is scheduled to begin in October. The eight-week, three-arm clinical trial of Hypericum perforatum first will compare the safety and efficacy of the herbal ingredient against placebo in treating depression ("The Tan Sheet" June 23, 1997, p. 18). Pfizer's Zoloft (sertraline), an Rx selective serotonin re-uptake inhibitor, will be used in the third arm of the trial to document the study's sensitivity, although the trial will not have sufficient power to compare sertraline and St. John's wort.
You may also be interested in...
NCCAM Omega-3 Fatty Acids Study To Commence In April
The National Institutes of Health is sponsoring several clinical trials on omega-3 fatty acids, including one investigating their effect on major depression and bipolar disorder and another studying fatty acids' antiarrhythmic effects.
NCCAM Omega-3 Fatty Acids Study To Commence In April
The National Institutes of Health is sponsoring several clinical trials on omega-3 fatty acids, including one investigating their effect on major depression and bipolar disorder and another studying fatty acids' antiarrhythmic effects.
NCCAM Omega-3 Fatty Acids Study To Commence In April
The National Institutes of Health is sponsoring several clinical trials on omega-3 fatty acids, including one investigating their effect on major depression and bipolar disorder and another studying fatty acids' antiarrhythmic effects.